MedTrace Logo

Phase II Iressa + Irradiation Followed by Chemo in NSCLC

NCT00333294 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-12-19

No results posted yet for this study

Summary

The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.

Conditions

Interventions

DRUG

Gefitinib

PROCEDURE

Radiation therapy

DRUG

Cisplatin

DRUG

Vinorelbine

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca France Medical Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333294 on ClinicalTrials.gov